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Recombinant human erythropoietin (Epo) is used to prevent and treat tumor-related anemia and improve
quality of life in cancer patients. Recent evidence suggested that Epo may adversely affect the survival of
selected cancer patients by promoting tumor growth, inhibition of apoptosis, and induction of migration. Epo
unfolds its effect on the Epo receptor (EpoR). We show—to the best of our knowledge for the first time—
significantly increased EpoR expression in clinical melanoma metastases and primary melanomas in comparison
with different sets of nevi by quantitative real-time reverse transcriptase-PCR, immunohistochemistry, and
western blot analysis. When assessing the functionality of the EpoR-signaling pathway, recombinant human Epo
led to the phosphorylation of JAK-2, signal transducers and activators of transcription 3 (STAT3), and ERK1/2 in
several of the melanoma cell lines that were analyzed. Besides, Epo counteracted cisplatin-induced cell death in
BLM and MV3 cells. Finally, Epo promoted cell migration of MV3 cells, whereas inhibition of the JAK/STAT and
ERK1/2 pathways reduced Epo-mediated migration. In summary, we show the overexpression of functional EpoR
expression in about half of the analyzed clinical melanoma metastasis specimens and show anti-apoptotic as
well as pro-migratory effects of Epo, which is of importance for the treatment of anemia in advanced melanoma.
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INTRODUCTION
Erythropoietin (Epo), a glycoprotein hormone, is one of the
most important stimulatory factors for erythropoiesis, which
promotes the proliferation and prevents apoptosis of erythroid
precursors allowing differentiation into maturated red blood
cells (Silva et al., 1996; Koury et al., 2002). Epo receptor
(EpoR) belongs to the cytokine receptor superfamily and
exerts its effects through receptor homodimerization, sub-
sequent phosphorylation of JAK2, and activation of signal
transducers and activators of transcription 3 and 5 (STAT3/5)
(Kirito et al., 1997). Moreover, Epo is also able to activate the
Ras-Raf-MEK-ERK pathway as well as PI3-kinase signaling in
different types of cells (Lee et al., 2004; Schmidt et al., 2004;
Lester et al., 2005).
Recombinant human Epo-stimulating agents can prevent
chemotherapy- and radiotherapy-mediated anemia in tumor
patients and improve quality of life (Rizzo et al., 2002), and
has been widely used as an alternative to red blood cell
transfusion. However, two recent randomized clinical trials
in patients with breast cancer (Leyland-Jones et al., 2005) and
head and neck cancer (Henke et al., 2003) reported a
negative outcome of recombinant human Epo-stimulating
agents on patients’ survival and tumor progression prompting
a boxed warning by the Food and Drug Administration
(www.fda.gov/cder/drug/early_comm/ESA.htm). Another ran-
domized, double-blind trial of Epo in non-small-cell lung
cancer with disease-related anemia was halted because of
unexpectedly high rates of thrombotic events (Wright et al.,
2007). In contrast to these results, other studies described no
negative effects of recombinant human Epo-stimulating
agents on tumor progression of squamous cell carcinoma of
the oral cavity and oropharynx (Glaser et al., 2001). In
patients receiving non-platinum chemotherapy for non-
myeloid malignancies, Epo caused an improvement in the
quality of life (Littlewood et al., 2001). A meta-analysis of 57
studies including 9,353 patients found that 36% of patients
treated with Epo or darbepoetin had a lower requirement for
transfusions than control subjects (Bohlius et al., 2006);
however, the relative risk of thromoboembolic events
increased by 67% in treated patients compared with the
control. Overall survival was analyzed for 8,167 patients
from 42 studies, which indicated that survival did not
improve after Epo or darbepoetin treatment; in contrast, the
possibility was raised that survival may even decrease
(Bohlius et al., 2006). Furthermore, several studies described
high EpoR expression in a variety of tumor samples and cell
lines such as brain tumors and glioma cell lines (Yin et al.,
2007), human ovarian cancer cells lines (Jeong et al., 2008),
non-small-cell lung carcinomas (Saintigny et al., 2007),
kidney cancer (Gong et al., 2006), prostate cancer (Arcasoy
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et al., 2005a) head and neck squamous cell carcinoma
(Mohyeldin et al., 2005; Arcasoy et al., 2005b), breast cancer
(Acs et al., 2001; Phillips et al., 2007), and melanoma cell
lines (Selzer et al., 2000; Kumar et al., 2005). Two recent
reviews describe all available studies and discuss the
controversy (Hardee et al., 2006; Sinclair et al., 2007).
One important criticism that was raised referred to the
specificity of the anti-EpoR antibody (C20) from Santa Cruz
Biotechnology (Santa Cruz, CA) (Elliott et al., 2006; Brown
et al., 2007). C20 recognizes three proteins in tumor cell lines
with 35, 66, and 100 kDa in molecular weight; the 66-kDa
band has been identified by liquid chromatography coupled
with mass spectrometry as the heat shock protein 70 (Elliott
et al., 2006; Brown et al., 2007). The other antibody (M-20)
from Santa Cruz (Santa Cruz Biotechnology) was found to
recognize the EpoR in western blot analysis but not in
immunohistochemistry (Elliott et al., 2006). A recent study
with gene amplification analysis of the EpoR locus using
1,083 tumor samples from 15 different tumor types showed a
rare amplification of the EpoR locus with frequencies similar
to other non-oncogenes (Sinclair et al., 2008). These
conflicting findings prompted us to investigate the expression
and functionality of EpoR in clinical melanoma samples. We
show increased EpoR expression in primary melanoma and
metastases and confirmed the functionality of EpoR signaling
in melanoma specimens, thus cautioning the use of Epo for
the treatment of anemia in these patients.
RESULTS
High EpoR expression in melanoma metastases
To determine the presumable role of EpoR in melanoma, we
first examined the transcription level as well as EpoR protein
expression in human melanoma samples using real-time
reverse transcriptase (RT)-PCR, western blot analysis, and
immunohistochemistry (Figures 1–3). Investigation of EpoR
transcription in benign nevi (n¼ 10) by real-time RT-PCR
showed an average expression value of 1.16 in relation to
normal human melanocytes (NHMs) (Figure 1a and e).
We used RNA from NHM as control in real-time RT-PCR
analysis. Bar graphs in Figure 1a–e show expression of EpoR in
human specimens relative to NHM. In dysplastic nevi (n¼10),
the level of EpoR transcripts was on average 3.48 times higher
relative to NHM (Figure 1b and e). The transition from benign
to dysplastic nevi reflected a significant increase in EpoR
expression (Po0.05). There was no difference in EpoR
expression between dysplastic nevi and primary melanoma
(Figure 1b, c and e). Further, in melanoma metastases we
observed a high EpoR expression that was on average 12.8
times higher relative to NHM (Po0.001) (Figure 1d and e). In
50% of the investigated melanoma metastasis samples the
EpoR expression was more than 20 times higher than in NHM
(Figure 1d and e). Thus, EpoR expression seemed an important
biological characteristic of metastasis.
To confirm the real-time PCR data on the protein level, we
used western blot analysis and immunohistochemistry
(Figures 2 and 3). First, we analyzed the EpoR expression in
different tissues and cells through western blot analysis
(Figure 2a), using the EpoR monoclonal antibody from R&D
systems (Wiesbaden-Nordenstadt, Germany) (LaMontagne
et al., 2006). According to the literature, human placenta
has been as positive control, as villous and extravillous
cytotrophoblast cells in human placenta are known to be
positive for EpoR expression (Conrad et al., 1996; Fairchild
Benyo and Conrad, 1999). Whereas EpoR mRNA was absent
in 12 of 16 (75%) benign nevi samples, EpoR was highly
expressed in placenta (Figure 2a). We observed a B58-kDa
band (Figure 2a), which is in concert with published data
(LaMontagne et al., 2006).
In melanoma metastases, the EpoR expression was
highly expressed in 17 of 25 (68%) samples (Figure 2a and
b), weakly expressed in 6 of 25 (24%) samples, and absent in
2 of 25 (8%) samples. In NHM, the EpoR was weakly
expressed in comparison with the melanoma cell lines A375,
BLM, and MV3, which showed a constitutive to high EpoR
expression, respectively (Figure 2a and b). In total, three of
ten (30%) investigated melanoma metastases samples also
expressed the Epo ligand, which allowed paracrine stimula-
tion of melanoma cells. From the investigated melanoma cell
lines, only MV3 cells were able to synthesize both Epo
protein and the EpoR (Figure 2b). To ascertain specificity of
the antibody, we used Epo protein for competition experi-
ments in combination with the monoclonal EpoR antibody
(LaMontagne et al., 2006) in western blot analysis showing
significant inhibition on binding of the Epo protein to its
receptor, resulting in a decreased EpoR signal in western blot
analysis when compared without competitor (Figure 2c).
To further assess the correlation between Epo and
EpoR, we performed immunohistochemistry investigations
(Figure 3). To confirm the specificity of the antibody, we
pursued different western blot and immunohistochemistry
approaches; we used placenta and adult kidney as positive
controls that have been described in the literature to harbor
positive as well as negative EpoR areas, that is, tubuli staining
positive and glomeruli being negative for EpoR expression
(Figures 2c and 3A) (Sairanen et al., 2006). A representative
set of immunohistostaining of nevi, primary melanoma, and
melanoma metastases is shown in Figure 3B. In the majority
of the investigated nevi samples the EpoR staining was low to
absent (Figure 3B). Furthermore, immunohistochemistry of
primary melanoma was positive for EpoR (Figure 3B) with
predominant membrane staining. Cutaneous melanoma
metastases showed nests of melanoma cells with intensive
membrane and cytoplasmatic staining (Figure 3B). For
statistical analysis, the immunohistochemistry staining was
semiquantitatively evaluated according to the staining
intensity, with a scale from 1 (lowest) to 12 (highest) EpoR
expression. EpoR expression was analyzed in 36 nevi, 40
primary melanoma and 41 melanoma metastases samples.
EpoR staining showed 80% of melanoma metastases (33 of
41) having the highest intensity of EpoR expression. In nevi,
only 25% of investigated samples (9 of 36) showed intensive
EpoR staining and in primary melanoma 52.5% of samples
(21 of 40) were highly positive. The EpoR expression in
melanoma metastases was significant compared with nevi
(Po0.0001) and primary melanoma (Po0.006). No signifi-
cant difference in EpoR expression existed between primary
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melanoma and nevi (Po0.059). Further, there was no
correlation between EpoR and Epo expression in the serial
sections (33 nevi, 37 primary melanomas, and 35 melanoma
metastases; data not shown).
EpoR signaling in melanoma
Next, we investigated the functionality of the EpoR by
treatment of melanoma cell lines with human recombi-
nant Epo and examined the effect of Epo on EpoR signaling
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Figure 1. Real-time PCR analysis of erythropoietin receptor (EpoR) expression in nevi and human melanoma specimens. Bar graphs show expression of EpoR in
human specimens relative to normal human melanocyte (NHM). (a) The expression of EpoR in five depicted benign nevi was on average 1.16-times lower
relative to NHM. (b) In five dysplastic nevi the EpoR mRNA was on average 3.48-times higher than in NHM. (c and d) The EpoR expression in primary melanoma
(n¼10) was 3.39-times and in melanoma metastases (n¼ 10) 12.8-fold higher in comparison with NHM. (e) Box plot of EpoR expression in benign nevi,
dysplastic nevi, primary melanoma, and cutaneous melanoma specimens (stage IV disease). Fold changes relative to NHM are depicted. Bar graphs in Figure
1a–e show expression of EpoR in human specimens relative to NHM. The results show EpoR expression on the RNA level in relation to NHM.
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Figure 2. Western blot analysis of erythropoietin receptor (EpoR) expression in different tissues and cutaneous melanoma metastases. (a) EpoR was
expressed in placenta and in one of eleven depicted nevi as well as in 20 of 21 depicted cutaneous melanoma metastases. EpoR protein was barely detectable
in healthy skin. EpoR was weakly expressed in normal human melanocytes (NHM) (a and b). The melanoma cell lines A375, BLM, and MV3 showed a
constitutive to high expression of EpoR. (b) In two of the four displayed cutaneous melanoma metastases, Epo protein was expressed constitutively to highly.
Only the MV3 melanoma cell line was positive for Epo protein. (c) Western blot analysis of EpoR with MV3 cells and placenta. The addition of Epo protein
significantly reduced the EpoR signal. (II) We used b-actin and a-tubulin as an internal control.
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Figure 3. Immunohistochemistry of erythropoietin receptor (EpoR). (A) Kidney tissue was used to prove the specificity of the EpoR antibody. Renal
glomeruli showed no staining, whereas the renal tubuli stained intensively in EpoR immunohistochemistry. Bar¼100 mm in (A-a), 50mm in (A-b), (A-d and
A-e), and 25 mm in (A-c). (B-I) A representative nevus negative for EpoR staining. (B-II) A representative sample of melanoma with predominant cytoplasmatic
EpoR staining. (B-III) Cutaneous melanoma metastasis showing a stronger and more homogeneous EpoR staining than primary melanoma. On higher
magnification (III-b) most cells showed cytoplasmatic and membrane staining. Bar¼ 50mm in I-a,II-a, III-a and 25mm in I-b, II-b, III-b.
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(JAK/STAT, MAPK pathways), apoptosis, cell proliferation,
and migration. The JAK/STAT pathway as well as MAPK/ERK
pathway are known to be activated in melanoma by
epithelial growth factor as we and others have described
recently (Mirmohammadsadegh et al., 2006, 2007; Lopez-
Bergami et al., 2008). On Epo treatment, phosphorylation of
JAK-2 (MV3 cells) and STAT3 in all the investigated
melanoma cell lines was detected (Figure 4a-I). Furthermore,
Epo induced the phosphorylation of ERK1/2 in all three
investigated cell lines with a maximum after 1 hour of
incubation (Figure 4b-I). Treatment of the melanoma cell
lines, A375, BLM, and MV3, with vehicle-control, 0.58%
sodium citrate, 0.58% sodium chloride, and 0.006% citric
acid for different time points shows no effects of phosphor-
ylation of the investigated proteins (Figure 4a-II and 4b-II). In
addition, Epo induced the transcription of the anti-apoptotic
gene Bcl-2 in MV3 by almost seven times, whereas it had
only a weak effect in A375 cells and no effect in BLM cells
(Figure 4c). To examine the role of STAT3 in the regulation of
transcription induced by Epo, we analyzed the STAT3 DNA-
binding activity by electrophoretic mobility shift assays in the
melanoma cell lines A375, BLM, and MV3 (Figure 4d). Epo
was able to induce the STAT3 DNA-binding complex very
strongly in MV3 in contrast to A375 and BLM, which is in
agreement with the upregulation of Bcl-2 transcription after
Epo treatment in MV3 (Figure 4c and d). The effect of Epo on
the phosphorylation of JAK2, STAT3, ERK1/2, and Bcl-2
transcription was more pronounced in MV3 cells than in
A375 and BLM cells, which is likely because of the increased
EpoR expression.
Epo inhibited apoptosis in melanoma cell lines
Recently, published data described a variety of inhibitory
effects of Epo on apoptosis induced by chemotherapeutic
agents (Chen et al., 2007; Li et al., 2007; Kim et al., 2008). To
assess an anti-apoptotic effect of Epo in melanoma, the
melanoma cell lines, BLM and MV3 were treated with 5U
per ml of Epo alone or in combination with 100 mM cisplatin
A375 BLM MV3
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Figure 4. Erythropoietin receptor (EpoR) signaling in melanoma. (a-I) Treatment of melanoma cell lines (A375, BLM, and MV3) with 5U per ml of Epo for 15
and 30minutes caused phosphorylation of JAK-2 and STAT3 in MV3 cells. a-Tubulin was used as internal control. (a-II) Treatment of melanoma cell lines A375,
BLM, and MV3 with vehicle-control, 0.58% sodium citrate, 0.58% sodium chloride, 0.006% citric acid for 15 and 30minutes for p-Jak-2, p-Stat3 and Stat3,
respectively. (b-I) Epo led to phosphorylation of ERK1/2 in A375, BLM, and MV3 after 1 hour of incubation. a-Tubulin was used as internal control. (b-II)
Treatment of A375, BLM, and MV3 with vehicle-control for and 3 hours and western blot analysis with p-Erk1/2 and Erk1/2. a-Tubulin was used as an
internal control. (c) Real-time reverse transcriptase (RT)-PCR analysis showing upregulation of Bcl-2 transcripts in A375 and MV3 melanoma cell lines
following Epo treatment (3 hours; 5U per ml of Epo); every experiment was repeated four times. (d) Electrophoretic mobility shift assay (EMSA) using
nuclear extracts of A375, BLM, and MV3 with consensus binding sites of STAT3 revealing an increased signal on Epo treatment in MV3 cells. The loading
controls are visible at the bottom of the blot.
www.jidonline.org 205
A Mirmohammadsadegh et al.
Erythropoietin Receptor in Melanoma
for 24 hours. Epo inhibited cisplatin-mediated apoptosis by
18% in BLM cells (Figure 5a) and 28% in MV3 (Figure 5b)
cells when compared with cisplatin-treated cells. The
statistical analysis was performed using the Kruskal–Wallis
test for cisplatin versus cisplatin/Epo treatment. (BLM cells:
P¼0.05; MV3 cells: P¼ 0.083, n¼3).
Epo induced migration of melanoma cell lines
The fact that EpoR expression was significantly higher in
melanoma metastases in comparison with nevi and primary
melanoma led us to investigate the effect of Epo on
melanoma cell migration. Previous studies have suggested
such an effect in breast cancer (Lester et al., 2005), squamous
cell carcinoma (Mohyeldin et al., 2005), and cervical cancer
(Hamadmad et al., 2008).
We investigated the effect of Epo on proliferation and cell
migration of melanoma cells in serum-free media using a
24-well cell migration assay (8mM pore size) and different
concentrations of Epo. Whereas there was no effect on
proliferation (Figure 6a) (MV3 P¼0.789; A375 P¼0.738;
BLM P¼0.392; Kruskal–Wallis test, each n¼5), migration of
MV3 cells was 1.8 times higher in comparison with control at
optimum concentrations (10Uml1, 16 hours) (Figure 6b)
(MV3 P¼0.024; Kruskal–Wallis test). Epo had no effect on
BLM cell migration (Figure 6c) (BLM P¼0.127 Kruskal–Wal-
lis test). Inhibition of the JAK/STAT pathway with AG490 as
well as of ERK1/2 signaling with U0126 abolished the
migratory effect of Epo (Figure 6d) (P¼ 0.047, Kruskal–Wallis
test, n¼3).
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DISCUSSION
Many studies on the role of Epo and EpoR expression in
tumor biology have yielded contradicting results (Hardee
et al., 2006; Osterborg et al., 2007; Sinclair et al., 2007). The
consistent finding of several publications is an increased level
of EpoR in various tumors and cancer cell lines (Acs et al.,
2001; Yasuda et al., 2003; Mohyeldin et al., 2005; Hardee
et al., 2006; Sinclair et al., 2007). The main criticism with
regard to these studies describing the overexpression of EpoR
has been the lack of specificity of the most widely used anti-
EpoR antibody (C-20, Santa Cruz Biotechnology) that also
recognized the heat shock protein 70, that is also highly
expressed in different human cancers (Elliott et al., 2006;
Brown et al., 2007). A recently published study by Sinclair
et al. (2008) found no difference between EpoR expression in
tumors and normal tissue.
Our study has addressed the EpoR expression in benign
and malignant pigmented lesions, which has not been
systematically performed to date. Our results showed a
significant EpoR overexpression in 50% of melanoma
metastases in comparison with primary melanoma and nevi,
and suggest an association between disease progression and
EpoR expression.
For western blot analysis and immunohistochemistry, we
used a monoclonal EpoR antibody that specifically reacts
with the amino acids #25–250 of the extracellular domain of
the EpoR (Jones et al., 1990). The full-length human EpoR
cDNA encodes a protein with 508 amino acids with a
calculated molecular weight of 55,065Da containing the 225
amino acid residue of the extracellular domain (EPOR_Hu-
man, expasy accession nr. 19235) (Winkelmann et al., 1990).
Three findings from our study confirm that the EpoR
antibody was specific: (i) the observed molecular weight of
approximately 56–60 kDa; (ii) the preincubation with recom-
binant human Epo and the consequent reduction of EpoR
signal intensity in western blot analysis, and (iii) the antibody
distinguished between positive and negative areas in the
kidney, in which glomeruli are negative and tubuli are
positive (Sairanen et al., 2006). In addition, the real-time RT-
PCR data further support EpoR upregulation in melanoma
metastases in comparison with nevi and primary melanoma,
which has previously been shown for NHM and melanoma
cell lines but not for freshly obtained patient specimens
(Selzer et al., 2000; Kumar et al., 2005). The study by Kumar
et al. (2005) found EpoR expression in two of the three
investigated human melanocyte preparations and a constitu-
tive expression of Epo and EpoR in all investigated melanoma
cell lines, suggested that an autocrine loop of Epo/EpoR
stimulation in melanoma. In contrast to this report, we have
no evidence for an autocrine loop in clinical melanoma, as
we were unable to show a correlation between Epo and EpoR
expression. Nevertheless, lesional endothelia could have
affected the real-time RT-PCR data; however, all clinical
lesions harbor endothelia to a similar extent. In addition,
immunohistochemistry analysis directly visualized positive
melanoma cells that exceeded signals from endothelia. In
addition, the functionality of signaling through the EpoR is
further strengthened by RNA and protein data.
The pro-migratory effects of Epo have been detected in
MV3 cells that bear high levels of EpoR and showed active
signaling after stimulation with Epo. The active signaling
through the EpoR was further supported by inhibition of the
JAK/STAT and MAPK pathways that reduced the pro-
migratory effects of Epo in melanoma cells. Thus, our data
are in accordance with published results, describing cancer
cell migration after Epo treatment in head and neck
squamous cell carcinoma cell lines (Mohyeldin et al.,
2005), cervical cancer cell lines (Hamadmad et al., 2008),
and breast cancer MCF-7 (Lester et al., 2005). However, the
migration rates in head and neck squamous cell carcinoma
cells and cervical cancer were several folds higher than in
melanoma cells, which may be due to their epithelial origin
in contrast to the neuroectodermal provenance of melanoma.
Apart from the impact on migration, Epo also displayed
anti-apoptotic effects by induction of Bcl-2 transcription,
which ultimately leads to increased survival of melanomas.
Even more so, Epo prevented melanoma cancer cells from
chemotherapy-mediated cell death, which is the goal of
therapy in advanced disease. Similar findings have been
recently published for renal carcinoma cells (Li et al., 2007),
the malignant glioma cell lines U87 and the cervical cancer
cell line HT 100 (Belenkov et al., 2004).
In summary, we show the overexpression of functional
EpoR expression in about half of the analyzed melanoma
metastases and show anti-apoptotic as well as pro-migratory
effects of Epo, which prohibit the use of Epo for the treatment
of anemia in advanced melanoma with intact EpoR signaling.
MATERIALS AND METHODS
Cell culture
Normal human melanocytes were cultured in phorbol 12-myristate
13-acetate-free melanocyte medium (both obtained from PromoCell,
Heidelberg, Germany). Cell culture was maintained in a 37 1C
incubator in a moist atmosphere of 5% CO2. The human melanoma
cell lines BLM, MV3, and A375 were cultured in DMEM (Invitrogen-
Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf
serum, 100U per ml of penicillin, and 100mg per ml of
streptomycin unless stated otherwise. A375 is a primary melanoma
cell line, (ATCC Number: CRL 1619, LGC Promochem GmbH,
Wesel, Germany), BLM and MV3 are frequently metastatic
melanoma cell lines (Van Muijen et al., 1991). Cisplatin was
obtained from Sigma-Aldrich, Taufkirchen, Germany. Recombinant
human Epo-alpha was obtained from Provitro, Berlin, Germany.
Tumor specimens
Nevi and cutaneous melanoma metastasis (stage IV disease before
the initiation of chemotherapy) samples were obtained from several
patients, who signed an informed consent. Clinical diagnosis was
obtained from histopathological analysis of one-half of the sample.
The other half was snap-frozen in liquid nitrogen and homogenized
using a dismembrator (Braun-Melsungen, Melsungen, Germany).
The powder was immediately transferred into ice-cold lysis buffer
containing 25mM hydroxyethylpiperazine ethanesulfonic acid pH
7.9, 50mM NaF, 15mM Triton X-100, 5mM EDTA, 100mM NaCl, and
one tablet protease inhibitor cocktail per 10ml buffer (Roche
Applied Science, Mannheim, Germany) for western blot analysis.
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The study was conducted according to the Declaration of Helsinki
Principles and was approved by the Institutional Review Board.
RNA extraction and melanin removal
Total RNA from fresh tumors, NHM, and melanoma cell lines were
obtained using TRIZOL (Invitrogen). Removal of melanin was per-
formed using RNAeasy kits (Qiagen, Hilden, Germany), as described
earlier (Nambiar et al., 2007). RNA specimens were analyzed by
microcapillary electrophoresis on LabChips using the Agilent 2100
Bioanalyzer (Agilent Technologies, Boeblingen, Germany).
Quantitative real-time PCR
cDNA synthesis of total RNA from fresh tumors was performed with
Taq-Man Reverse Transcription Reagents #N8080234 (Applied
Biosystems, Foster City, CA) using random hexamers and the primers
and probes for EpoR (Hs00181092 m1) and 18S (Hs99999901_s1)
(Applied Biosystems). All samples were amplified simultaneously in
triplicates.
Western blot analysis
Cultured cells or homogenized tissue were washed twice with ice-
cold phosphate-buffered saline and lysed in lysis buffer (see above).
The samples were pretreated with ultrasound (10 pulses on ice;
Sonoplus, Bandelin Electric, Berlin, Germany) and were centrifuged
at 14,000 g for 20minutes at 4 1C. The protein concentration of the
cellular extracts was determined using the advanced protein assay
reagent (Cytoskeleton, Denver, CO). A total of 20 mg of protein
extract were electrophoresed on 4–12% NuPage Bis-Tris-Glycine
gels (Invitrogen) for 2 hours at 120V. Proteins were blotted onto
polyvinylidene fluoride membranes (Roth, Karlsruhe, Germany) at
160mA for 60minutes using a tank blot system. The membranes
were blocked with 1% non-fat dry milk powder in 10mM Tris-HCl
(pH 7.5), 150mM NaCl, and 0.05% Tween 20 Tris buffered saline
with Triton 100 buffer for 1 hour at 4 1C and washed thrice with Tris
buffered saline with Triton 100. Immunostaining was performed
using the EpoR mouse monoclonal antibody, Cat. Nr. MAB307 and
rabbit polyclonal antibody, Cat. AB-286-NA (R&D Systems).
Antibodies against P-ERK1/2, ERK1/2, STAT3, P-STAT3, and P-JAK-
2 were from Cell Signaling, New England Biolabs, Frankfurt,
Germany. a-Tubulin and b-actin antibodies were purchased from
Oncogene Research Products, Calbiochem, Darmstadt, Germany.
Bound antibody was visualized using the chemiluminescence
detection system (GE Healthcare, Freiburg, Germany) following
the supplier’s instructions.
FACS analysis using the annexin-V/PI method
The appearance of phosphatidylserine on the extracellular side of
membrane was evaluated using annexin-V/PI (propidium iodide)
method. The melanoma cell lines A375, BLM, and MV3 were
exposed to Epo and cisplatin, trypsinized, and washed twice in ice-
cold phosphate-buffered saline before resuspension in 1 binding
buffer (Invitrogen). Thereafter, 5 ml of annexin V-FITC (Vybrant;
Invitrogen) and 1 ml propidium iodide (100mgml1) were added to
100ml of cell suspension and incubated for 15minutes at room
temperature protected from light. Finally, 400 ml of binding buffer
were added to the samples and handled ice-cold until analysis.
The fluorescent signals of FITC and PI were detected by FL1 at
518 nm and FL2 at 620 nm, respectively, on a FACSCalibur (Becton
Dickinson Biosciences, Heidelberg, Germany) and apoptotic cells
(annexin-V-positive/PI-negative) were quantified.
Proliferation assay
BrdU assays were performed according to the supplier’s instructions
(Roche Applied Science).
Preparation of nuclear extracts
Nuclear extracts were prepared from treated A375 and BLM cells as
described (Hassan et al., 2008). Briefly, cells were washed with ice-
cold phosphate-buffered saline buffer and harvested by adding
500ml of buffer A (20mM Hepes, pH 7.9; 10mM NaCl, 0.2mM EDTA;
and 2mM dithiothreitol) containing protease inhibitors and incu-
bated on ice for 10minutes. The supernatant was discarded after
centrifugation at 14,000 r.p.m. for 3minutes. The pellet was
resuspended in 50ml of buffer C (20mM Hepes, pH 7.9; 420mM
NaCl, 0.2mM EDTA; 2mM dithiothreitol; 1mM Na3VO4, 25%
glycerol) containing protease inhibitors at 4 1C for 20minutes
before centrifugation at 14,000 r.p.m. for 3minutes. The supernatant
was collected without disturbing the pellet and stored at 80 1C
until use.
Electrophoretic mobility shift assay
The details of electrophoretic mobility shift assay have been
described elsewhere (Hassan et al., 2008). The double-stranded
synthetic oligonucleotides carrying a defined binding site for STAT3
(Santa Cruz Biotechnology) were end-labeled with [g-32P] ATP
(Hartmann Analytika, Munich, Germany) in the presence of T4
polynucleotide kinase (Genecraft, Mu¨nster, Germany). A total of
4mg of nuclear extracts were bound to a labeled probe in a total
volume of 30ml for 30minutes at room temperature in binding buffer
(10mM Tris, pH 7.5; 50mM NaCl, 1mM EDTA; 1mM MgCl2; 0.5mM
dithiothreitol and 4% glycerol). The specificity of binding was
analyzed by competition with an unlabeled oligonucleotide and/or
with supershift assays. The competition assay was performed in the
same manner except that unlabeled probes containing either STAT3
sequences were incubated with nuclear extracts for 20minutes at
room temperature before adding the labeled probes. Electrophoresis
was performed for 3 hours at 100V in 0.5 Tris-borate-EDTA
running buffer at room temperature. The dried gel was visualized by
exposure to high performance autoradiography film.
Immunohistochemistry
For EpoR immunohistochemistry staining, we used 36 nevi, 40
primary melanoma, and 41 melanoma metastases from different
patients. For immunohistochemistry staining of Epo versus EpoR we
used 33 nevi, 37 primary melanoma, and 35 melanoma metastases.
Paraffin-embedded sections were dried overnight by 65 1C. The
sections were further treated as follows: thrice for 7minutes with
xylol, twice for 2minutes with 100% ethanol, 2minutes with 96%
ethanol, 2minutes with 70% ethanol, twice for 2minutes with H2O,
and 2minutes with washing buffer from DAKO (DAKO REAL
Detection System, Hamburg, Germany). The sections were un-
masked in 98 1C water bath for 20minutes and cooled for 10minutes
in EDTA buffer in cooled water bath and subsequently washed twice
for 5minutes in wash buffer (DAKO REAL Detection System). For
immunostaining the sections were blocked with 2% normal goat
serum for 20minutes, then the goat serum was removed and the
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sections were incubated with first antibody for 2 hours at room
temperature. The further steps were according to the DAKO real kit
instructions. The evaluation of immunohistochemical staining was
semiquantitative at 200–400 times magnification with a light
microscope (Carl Zeiss, Go¨ttingen, Germany) according to published
standards (Morris et al., 2001). For the assessment, four representa-
tive fields were assessed per section. The immunostaining intensity
was evaluated by using a semiquantitative score based on the
percentage of positive cells in relation to the total number of tumor
cells. The intensity of staining was evaluated with 0, 1 (þ ), 2 (þ þ ),
or 3 (þ þ þ ) and the percentage of staining cells were judged with
1 (o25%), 2 (25–50%), 3 (51–75%), or 4 (475%) (Morris et al.,
2001). Both values were multiplied to obtain a semiquantitative
score. The analysis was performed using SPSS Statistics software
(SPSS, Munich, Germany).
Migration assay
The migration assays were carried out using serum-free media and
the QCM 24-Well colorimetric cell migration assay with 8 mM pore
size. The migration assays were performed according to the
supplier’s instructions (Chemicon, Millipore, Billerica, MA).
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